key: cord-0930973-fdwpwuk9
authors: Alislambouli, Mawaddah; Veras Victoria, Andy; Matta, Jyoti; Yin, Faye
title: Acquired thrombotic thrombocytopenic purpura following Pfizer COVID‐19 vaccination
date: 2021-11-16
journal: EJHaem
DOI: 10.1002/jha2.342
sha: faf1cfb40070623107f34bc3835432d8bd9c9565
doc_id: 930973
cord_uid: fdwpwuk9

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare disease and has occasionally been described after vaccination, especially against viral agents. We present a case of a patient who presents with the classic pentad of TTP a few days after receiving the first dose of the mRNA Pfizer COVID‐19 vaccine. To our knowledge, this is the second report of a de novo TTP following mRNA Pfizer COVID‐19 vaccination.

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare disease with an incidence of 3-10 cases per million adults per year.

The disease is defined by a severe reduction in the activity of von Willebrand factor-cleaving protease ADAMTS 13, which is mainly caused by the presence of inhibitory antibodies. It is characterized by the microvascular aggregation of platelets that cause thrombocytopenia, microangiopathic hemolytic anaemia, and sometimes organ damage, which were historically defined as a pentad, typically presenting in <10% of patients with aTTP [1] . ATTP has occasionally been described after vaccination, especially against viral agents. We present a case of a patient who presents with the classic pentad of TTP a few days after receiving the first dose of the mRNA Pfizer COVID-19 vaccine. 

D A Y 1 D A Y 3 D A Y 7 D A Y 1 4 D A Y 2 1 D A Y 2 9 D A Y 7 2 H G B G / L 0 50 100 150 200 D A Y 1 D A Y 3 D A Y 7 D A Y 1 4 D A Y 2 1 D A Y 2 9 D A Y 7 2

We present a case of a 61-year-old male patient with no past medical history who developed TTP 5 days after the first dose of Pfizer COVID-19 vaccination. He was treated with plasmapheresis, corticosteroids and rituximab with a rapid and excellent response. Given the clinical presentation, lab results and lack of thrombosis, Vaccine-induced TTP was less likely and TTP linked to COVID-19 vaccination was the most likely diagnosis.

To the best of our knowledge, this is the second report of a de novo TTP following mRNA Pfizer COVID-19 vaccination, and the third report of aTTP following COVID-19 vaccination. De Bruijn et al. [2] reported the first case of a 38-year-old woman with TTP at 2 weeks following the first dose of Pfizer COVID vaccine. Al-Ahmad et al. [3] reported a case of a 37-year-old man who developed TTP at 10-15 days after the AstraZeneca-Oxford COVID-19 vaccination. Also, a few other cases of TTP development following Pfizer and AstraZeneca-Oxford COVID-19 vaccination are mentioned in Table 1 .

Vaccination in general is an important part of preventive medicine.

Rarely vaccination, especially against viral infection, such as influenza vaccine [4] , has been associated with autoimmune pathology including acquired TTP.

The mechanism linking TTP with COVID-19 vaccines is poorly 

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015

First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination

Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca-Oxford COVID-19 vaccine

Influenza-associated thrombotic microangiopathies

Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events

Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine

How to cite this article: Alislambouli M, Veras Victoria A, Matta J, Yin F. Acquired thrombotic thrombocytopenic purpura following Pfizer COVID-19 vaccination

The authors thank Laixin Sun, MD, Department of Pathology for providing photograph (Figure 1 ).

The authors declare that they have no conflict of interest.

Mawaddah Alislambouli MD https://orcid.org/0000-0003-3589-